Declining prevalence of multidrug-resistant but comparatively high quinolone-resistant tuberculosis in Heilongjiang Province, China: 2013–2022 trend
Open Access
- 2 April 2026
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Abstract
The spread of multidrug-resistant tuberculosis (MDR-TB) remains a major problem globally. China is the high-burden country for TB, TB/HIV and MDR/rifampiciKeywords
Funding Information
- the Grant for Innovation Team Program of Heilongjiang Province
- National Natural Science Foundation of China (82272345)
This publication has 11 references indexed in Scilit:
- Tuberculosis in the Russian Federation: Prognosis and Epidemiological Models in a Situation After the COVID-19 PandemicJournal of Epidemiology and Global Health, 2023
- Efficacy of Tuberculosis Treatment in Patients with Drug-Resistant Tuberculosis with the Use of Bedaquiline: The Experience of the Russian FederationAntibiotics, 2022
- Persistently high prevalence of primary resistance and multidrug resistance of tuberculosis in Heilongjiang Province, ChinaBMC Infectious Diseases, 2016
- Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort studyThe Lancet, 2012
- National Survey of Drug-Resistant Tuberculosis in ChinaNew England Journal of Medicine, 2012
- Susceptibility Test Methods: Mycobacteria, Nocardia , and Other Actinomycetes2011
- Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes2011
- Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011 Update2011
- Extensively Drug-Resistant Tuberculosis in South Korea: Risk Factors and Treatment Outcomes among Patients at a Tertiary Referral HospitalClinical Infectious Diseases, 2008
- Worldwide Emergence of Extensively Drug-resistant TuberculosisEmerging Infectious Diseases, 2007